TLR7 and systemic lupus erythematosus: Advancing from the earlier encouraging prototypes, IRS-661 (TLR7 specific) and IRS-869 (TLR9 specific), a dual-function targeting both TLR7 and TLR9 antagonist, IRS-954 was developed for the treatment of SLE (Barrat et al., 2005).